Examining the achondroplasia treatment landscape with a focus on BBIO's infigratinib, BMRN's Voxzogo (vosoritide) & ASND's TransCon CNPTicker(s): BBIO, BMRN, ASND
Institution: Kentucky Children's Hospital
- Clinical geneticist and Chief, Division of Pediatric Genetics and Metabolism at Kentucky Children's Hospital; formerly Associate Professor of Pediatric Genetics at University of Arkansas for Medical Sciences.
- Manages 5 patients with achondroplasia in additton to patients with AKT pathway issues.
- Research led to a report with the first cohort of patients with SATB2-associated syndrome (SAS) and participates in the evaluation and treatment of individuals of all ages with birth defects, intellectual disabilities and other genetic disorders with a particular interest in connective tissue disorders and craniofacial anomalies.
Please describe your clinical practice, in particular with treating achondroplasia patients, and research in the space.Added By: max_admin
How many patients do you treat with achondroplasia? What treatment options do they have?Added By: max_admin
What is the mechanism of action of a C-type natriuretic peptide like vosoritide, how does it regulate bone growth?Added By: max_admin
Change from baseline in growth velocity after one year of treatment with vosoritide, the primary endpoint, was 1.6 cm/yr. How satisfactory is this result?Added By: max_admin
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.